Pharma cos may see short-term price blip: Ind-Ra

Any potential tariffs on pharmaceutical imports into the US are unlikely to impact the credit profiles of Indian firms except for a short-term pricing blip, according to a report by India Ratings......

Indian pharma eyes US gains as $63.7 bn patent cliff nears

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025–29,......

Sun Pharma Q4 profit down 19% at Rs 2,149.8 cr, revenue up 8%

India’s largest drug maker Sun Pharmaceutical on Thursday posted a decline of 19 per cent year-on-year (Y-o-Y) for its consolidated net profit for the fourth quarter of the financial year 2025......

Glenmark buys certain OTC drugs from Wockhardt in US

Glenmark Pharmaceuticals Ltd on Tuesday said it has acquired the approved generic versions of certain over-the-counter drugs from Wockhardt Ltd in the US. The acquisition by the company's......